Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.
KY2025-328-02
Phase 3 small_molecule active
Quick answer
Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months. for Post-stroke Epilepsy is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Post-stroke Epilepsy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active